U.S. pharma big copyright scrapped two experimental weight loss capsules final calendar year—a the moment-every day pill, lotiglipron, resulting from elevated liver enzymes as well as a twice-every day tablet, danuglipron, as a result of solid side effects—but CEO Albert Bourla has explained the company is set to “Perform and acquire” while